Viracta Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $55.49 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Viracta Therapeutics Inc had its IPO on 2005-09-27 under the ticker symbol VIRX.
The company operates in the Healthcare sector and Biotechnology industry. Viracta Therapeutics Inc has a staff strength of 41 employees.
Shares of Viracta Therapeutics Inc opened at $1.31 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.31 - $1.38, and closed at $1.36.
This is a +2.26% increase from the previous day's closing price.
A total volume of 13,674 shares were traded at the close of the day’s session.
In the last one week, shares of Viracta Therapeutics Inc have slipped by -6.85%.
Viracta Therapeutics Inc's Key Ratios
Viracta Therapeutics Inc has a market cap of $55.49 million, indicating a price to book ratio of 1.1822 and a price to sales ratio of 0.
In the last 12-months Viracta Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-53966000. The EBITDA ratio measures Viracta Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Viracta Therapeutics Inc’s operating margin was 0% while its return on assets stood at -40.89% with a return of equity of -89.59%.
In Q2, Viracta Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Viracta Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.42 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Viracta Therapeutics Inc’s profitability.
Viracta Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1483. Its price to sales ratio in the trailing 12-months stood at 0.
Viracta Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $76.86 million
- Total Liabilities
- $15.21 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Viracta Therapeutics Inc ended 2023 with $76.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $76.86 million while shareholder equity stood at $40.78 million.
Viracta Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $15.21 million in other current liabilities, 4000.00 in common stock, $-239567000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.29 million and cash and short-term investments were $72.87 million. The company’s total short-term debt was $4,688,000 while long-term debt stood at $20.79 million.
Viracta Therapeutics Inc’s total current assets stands at $74.56 million while long-term investments were $0 and short-term investments were $58.57 million. Its net receivables were $312000.00 compared to accounts payable of $3.23 million and inventory worth $-312000.00.
In 2023, Viracta Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Viracta Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Viracta Therapeutics Inc stock is currently trading at $1.36 per share. It touched a 52-week high of $5.75 and a 52-week low of $5.75. Analysts tracking the stock have a 12-month average target price of $8.75.
Its 50-day moving average was $1.41 and 200-day moving average was $1.61 The short ratio stood at 7.85 indicating a short percent outstanding of 0%.
Around 296.3% of the company’s stock are held by insiders while 6121.2% are held by institutions.
Frequently Asked Questions About Viracta Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company’s development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor; and VRx-510, a preclinical-stage PDK-1 inhibitor. The company was formerly known as Sunesis Pharmaceuticals, Inc. and changed its name to Viracta Therapeutics, Inc. in February 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.